Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Division to Present Initial Findings of UK 100,000 Genomes Project Data at Inaugural Conference

Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that Helomics CTO Dr. Mark Collins will speak during the scientific session of the inaugural UK 100,000 Genomes Project (“UK100K GP”) conference, and will participate in an invite-only session on the expansion of the UK100K GP to 5 Million genomes. According to the update, Helomics partnered with the UK100K GP in November 2018 to utilize whole genome and outcome data from the project to advance its efforts to build predictive models of various cancers. “This partnership is key to our approach of building AI-driven predictive models. We are delighted to participate in the scientific spotlight session, panel discussion and an invite-only session on the expansion of the UK 100,000 Genomes Project to 5 million genomes,” stated Dr. Collins. “The depth of both the genomic and clinical data for ovarian cancer from the project is best-in-class, yielding useful benchmarks to validate our models. Over the next year, we intend to explore additional projects to enable use of our AI-driven predictive models to improve outcomes for ovarian cancer patients in the UK, as well as seek partnerships with UK pharma companies for the development of new precision ovarian cancer therapies.”

To view the full press release, visit

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, 38,000+ specific to ovarian cancer. The company’s data is highly differentiated, having both drug response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI. Bookmark the permalink.

Comments are closed.